WALTHAM, Mass., July 22 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. , today announced the launch of an enhanced test report format and information package for the company's Heart Health Genetic Test. The test is currently marketed under the brand name Gensona(R) Heart Health Genetic Test by Quixtar/Amway. The new report will include quantified risk information on heart attack and coronary artery disease generated from clinical studies and conducted by the company. The company believes that this enhanced report format will provide individuals and their physicians more complete information about a person's inflammation-based genetic risk factor for a heart attack. The new package also provides information on the science behind the genetic test and information to help people understand preventive measures and actions that can be taken to lower the risk of heart disease.
In addition, the company will conduct scientific lectures on the Gensona(R) test for interested Quixtar/Amway individual business owners at their scheduled conferences. The first of these lectures will be on Saturday morning and afternoon, July 26, 2008 at the Nardone/Melillo/Callendar conference at the Radisson Valley Forge Hotel & Convention Center in Valley Forge, PA. Thousands of attendees are expected at the conference.
Lewis H. Bender, Chief Executive Officer at Interleukin Genetics, commented, "Heart disease is by far the leading killer of Americans. Individuals with different interleukin gene variations have vastly different clinical trajectories for heart disease progression. The ability to know your individual genetic predisposition for this disease is a new and powerful tool to allow a customer and their physicians to design the best preventive care for that person."
About Coronary Artery Disease
Coronary artery disease (CAD) is an inflammatory disease in which plaque builds up inside the coronary arteries. These arteries supply your heart muscle with oxygen-rich blood. Plaque is made up of fat, cholesterol, and other substances found in the blood. When plaque builds up in the arteries, the condition is called atherosclerosis. Variation in interleukin genes has shown to be associated with different degrees of CAD risk. Over time, CAD can weaken the heart muscle and lead to heart attack and arrhythmias. CAD is the most common type of heart disease and is the leading cause of death in the United States for both men and women. Lifestyle changes, medicines, and/or medical procedures can effectively prevent or treat CAD in most people. Certain cholesterols have also been associated with increased CAD risk. According to the American Heart Association, over 105 million American adults have total blood cholesterol values of 200 mg/dL and higher, and 36.6 million American adults have levels of 240 or above. Doctors consider total cholesterol levels of 240 mg/dL or greater high in adults and levels from 200 to 239 mg/dL borderline-high.
About Interleukin Genetics
Interleukin Genetics, Inc. , is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
CONTACT: Media: Lisa Rivero of LaVoie Group, +1-978-745-4200 ext. 106,
lrivero@lavoiegroup.com, or Investors: Melanie Friedman of Stern Investor
Relations, +1-212-362-1200, melanie@sternir.com, both for Interleukin
Genetics, Inc.
Web site: http://www.ilgenetics.com/
